Skip to content

Outcomes and risk stratification

TL;DR — HHD risk is multidimensional: pressure trajectory, LV mass/geometry, strain, fibrosis, atrial disease, biomarkers, kidney function, diabetes, obesity and established clinical disease all matter. LVH is prognostic, and regression is associated with fewer events, but no HHD-specific score has proven that adding advanced imaging improves treatment decisions (Okin 2004, PMID 15547161; Devereux 2004, PMID 15547162). ECG-LVH predicts stroke, CMR/echo phenotypes predict HF and death, and AF creates a high-risk feedback loop (Yi 2020, PMID 32504899; Aune 2023, PMID 36626102). REMODEL’s NT-proBNP/hs-troponin strata produced large hazard ratios but require external validation (Sharp 2026, PMID 41771092). A useful hierarchy starts with absolute clinical risk and sustained BP, then adds phenotype only when it changes classification or management.

1. Outcomes that should be separated

Domain Endpoint examples Why separation matters
Remodeling LVH onset/regression, fibrosis, GLS Surrogate or intermediate outcome
Rhythm Incident AF, AF burden, ventricular arrhythmia Detection-intensity dependent
HF First HF, recurrent hospitalization, EF transition Syndrome definition varies
Vascular Stroke, MI, revascularization Not necessarily mediated by cardiac remodeling
Kidney eGFR decline, albuminuria Cause, consequence and treatment safety
Mortality Cardiovascular, HHD-attributed, all-cause Adjudication/coding differences
Patient-reported Symptoms, function, treatment burden Often absent from HHD cohorts

Composite endpoints must report components because intensive BP or HF drugs may affect hospitalization more than cardiovascular death.

2. Baseline LVH

LVH predicts cardiovascular and all-cause outcomes beyond measured BP, but magnitude depends on modality and population (Lauer 1995, PMID 7606829; Stewart 2018, PMID 30408469).

Community syntheses extend this pattern across LV mass, systolic/diastolic function, atrial measures and strain, but question the incremental utility of screening echo in all hypertensive adults (Vasan 2021, PMID 34081212).

In MAVI, 1,019 hypertensive adults without prevalent cardiovascular disease had LV mass compared with a predicted value based on sex, workload and height. Excess mass predicted events beyond conventional LVH and risk factors (de Simone 2002, PMID 12364349).

LVH representation Strength Limitation
ECG voltage/product Cheap, prognostic electrical phenotype Low anatomical sensitivity
Echo mass index Widely available Geometry, observer and indexation variability
CMR mass index Reproducible reference anatomy Cost and access
Relative wall thickness Adds geometry Threshold/load dependent
Predicted/inappropriate mass Integrates workload/body size Model portability

3. ECG-LVH and stroke

A meta-analysis of hypertensive cohorts linked ECG-LVH to subsequent stroke, supporting electrical LVH as a risk marker even when anatomical sensitivity is poor (Yi 2020, PMID 32504899).

This is not paradoxical: a test can have low sensitivity for echo-LVH yet identify a high-risk electrical phenotype when positive (Pewsner 2007, PMID 17726091; Bressman 2020, PMID 32194027).

4. Serial regression

Study Serial measure Association with outcomes
LIFE ECG, 9,193 Cornell product Each 1-SD lower in-treatment value: composite HR 0.86 (95% CI 0.82–0.90)
LIFE echo, 941 LV-mass index Each 1-SD (25.3 g/m²) lower: composite HR 0.78 (0.65–0.94)
Regression meta-analysis Echo LVH regression/persistent normal mass Total cardiovascular events HR 0.54 (0.35–0.84)

Sources: Okin 2004 (PMID 15547161), Devereux 2004 (PMID 15547162), Pierdomenico 2010 (PMID 20414193).

Association persists after adjustment but can reflect achieved BP, adherence, treatment allocation, comorbidity and regression biology. STEP found that preventing new ECG-LVH did not explain most intensive-treatment event benefit (Deng 2023, PMID 37259845).

5. Geometry and transition

Concentric remodeling/LVH often carries high risk, but normal and eccentric geometry also occur in HFpEF. The classical concentric-to-dilated pathway is not universal (Nadruz 2015, PMID 24804791; Shah 2013, PMID 24097113).

Transition Potential interpretation Competing explanation
Normal → concentric remodeling Pressure adaptation Aging/loading variation
Concentric remodeling → LVH Accumulated load Obesity/CKD/valve disease
LVH → HFpEF Stiffness/atrial/microvascular failure AF, obesity phenotype, ischemia
LVH → HFrEF Maladaptive remodeling Interval MI, tachycardia, other cardiomyopathy
LVH regression Treatment response Measurement/load regression to mean

6. Strain and composite markers

In 1,600 HHD patients with repeat echo, LV mass-to-strain ratio predicted LVH change and later cardiovascular death/HF hospitalization. As a continuous measure, adjusted HR was 1.044 per 1 g/m² per %; a threshold ≥6.52 carried HR 2.267 (95% CI 1.520–3.381) (Hwang 2025, PMID 40970541).

An earlier asymptomatic HHD cohort developed an LV-strain risk score with prognostic association, but single-center thresholds require external calibration (Saito 2016, PMID 27344417).

Load dependence, vendor algorithms and data-driven cutoffs constrain use as treatment triggers.

7. CMR phenotypes

CMR measures mass, volumes, geometry, strain, LGE, T1 and ECV. In a 756-person HHD referral cohort followed median 7.1 years, baseline CMR phenotype was associated with clinical outcomes; referral selection and absence of randomized surveillance limit causal inference (Lertsiripatarajit 2026, PMID 41953289).

Marker Risk signal Validation need
LV mass/geometry Global remodeling burden Cross-population thresholds
LGE Focal scar Etiologic specificity
Native T1/ECV Diffuse tissue change Vendor/field-strength calibration
GLS/feature tracking Early dysfunction Software standardization
Perfusion reserve Microvascular disease Reproducible outcome threshold

Fibrosis is mechanistically compelling but has no HHD-specific threshold proven to improve outcomes when targeted (González 2024, PMID 38084597).

8. Biomarker staging

REMODEL prospectively followed 1,054 asymptomatic adults with essential hypertension after CMR and biomarker sampling. Within-cohort thresholds were NT-proBNP 152 pg/mL and hs-troponin T 12.7 pg/mL (Sharp 2026, PMID 41771092).

Stratum Event association
Neither marker elevated Reference
One elevated HR 3.44 (95% CI 1.71–6.94)
Both elevated HR 17.11 (8.12–36.09)

The wide CI, data-derived thresholds, assay dependence and need for external calibration preclude calling this an established staging system.

9. Diastolic dysfunction and atrial disease

In 283 community hypertensive adults, diastolic dysfunction predicted MACE with HR 2.5 (95% CI 1.20–5.25) over mean 5.4 years (Zhou 2022, PMID 35698035).

Hypertension itself was associated with AF RR 1.50 across 68 cohorts; AF then increases stroke and HF risk (Aune 2023, PMID 36626102). LA size/strain and rhythm should therefore be interpreted jointly, not as independent checklist points.

10. Clinical risk dominates advanced markers

High-impact clinical factor Why it matters
Sustained/ambulatory BP Ongoing causal exposure
Prior CVD Raises absolute benefit from prevention
CKD/albuminuria Risk plus treatment constraint
Diabetes Vascular/HF risk and trial-context difference
Age/frailty Absolute risk and harm tradeoff
Smoking/lipids Competing vascular pathways
Established HF/AF Changes therapy directly

Blood-pressure lowering reduces events across prior-CVD strata, so advanced phenotyping should not delay treatment of established risk (BPLTTC 2021, PMID 33933205).

In the phenotype-enriched LIFE population, losartan-based therapy reduced the composite outcome versus atenolol-based therapy, providing a trial anchor for risk reduction without proving a geometry-guided strategy (Dahlöf 2002, PMID 11937178).

11. Sudden death and ventricular arrhythmia

LVH is associated with ectopy and sudden death in older literature, but uncomplicated hypertensive LVH has not been isolated convincingly as a cause of sustained ventricular arrhythmia independent of occult CAD and electrolyte disturbance (Shenasa 2017, PMID 28285801; Nadarajah 2021, PMID 33674703).

Therefore:

  • LVH alone is not an HHD-specific ICD indication.
  • Syncope, scar, reduced EF, ischemia and documented arrhythmia require conventional evaluation.
  • Risk claims should distinguish nonsustained ectopy from sustained VT/VF and sudden death.

12. Proposed research risk matrix

This matrix is not validated for clinical use.

Axis Lower-risk evidence Higher-risk evidence
Pressure Controlled home/ABPM Persistent nighttime/24-hour elevation
LV Normal mass/GLS LVH plus impaired GLS
Tissue No LGE/low ECV within reference Scar or high diffuse-fibrosis measure
Atrium Normal volume/function, sinus rhythm LA failure or AF
Biomarker NP/troponin below calibrated thresholds Both elevated
Clinical No CKD/CVD/HF CKD, prior CVD, clinical HF

Its research value would be tested by incremental discrimination, calibration, decision curves and randomized phenotype-triggered intervention—not only a higher c-statistic.

Open questions

  • Does any advanced marker improve treatment decisions beyond absolute clinical risk and ABPM? (Sharp 2026, PMID 41771092; Hwang 2025, PMID 40970541)
  • Is remodeling regression a mediator, modifier or adherence marker? (Pierdomenico 2010, PMID 20414193; Deng 2023, PMID 37259845)
  • Can a multimodal model calibrate across sex, ancestry, obesity, CKD and scanner/assay platforms? (Lertsiripatarajit 2026, PMID 41953289)
  • Which HHD outcomes should be primary in prevention trials: incident HF, recurrent HF, AF, stroke or a hierarchical composite? (Nwabuo 2020, PMID 32016791)

References

  1. Okin PM, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343-9. PMID 15547161
  2. Devereux RB, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292:2350-6. PMID 15547162
  3. Yi S, et al. Prediction of stroke with electrocardiographic left ventricular hypertrophy in hypertensive patients: A meta-analysis. J Electrocardiol. 2020;61:27-31. PMID 32504899
  4. Aune D, et al. Blood pressure, hypertension and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2023;38:145-178. PMID 36626102
  5. Sharp A, et al. Role of natriuretic peptides and cardiac troponins in staging hypertensive heart disease: the REMODEL study. Eur J Heart Fail. 2026. PMID 41771092
  6. Lauer MS. Left ventricular hypertrophy and cardiovascular prognosis. Cleve Clin J Med. 1995;62:169-75. PMID 7606829
  7. Stewart MH, et al. Prognostic Implications of Left Ventricular Hypertrophy. Prog Cardiovasc Dis. 2018;61:446-455. PMID 30408469
  8. de Simone G, et al. Prognosis of inappropriate left ventricular mass in hypertension: the MAVI Study. Hypertension. 2002;40:470-6. PMID 12364349
  9. Pewsner D, et al. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ. 2007;335:711. PMID 17726091
  10. Bressman M, et al. Determination of Sensitivity and Specificity of Electrocardiography for Left Ventricular Hypertrophy in a Large, Diverse Patient Population. Am J Med. 2020;133:e495-e500. PMID 32194027
  11. Pierdomenico SD, et al. Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis. Am J Hypertens. 2010;23:876-81. PMID 20414193
  12. Deng Y, et al. Intensive Blood Pressure Lowering Improves Left Ventricular Hypertrophy in Older Patients with Hypertension: The STEP Trial. Hypertension. 2023;80:1834-1842. PMID 37259845
  13. Nadruz W. Myocardial remodeling in hypertension. J Hum Hypertens. 2015;29:1-6. PMID 24804791
  14. Shah AM. Ventricular remodeling in heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2013;10:341-9. PMID 24097113
  15. Hwang IC, et al. Left Ventricular Mass-to-Strain Ratio to Predict Change in Left Ventricular Hypertrophy and Prognosis in Hypertensive Heart Disease. J Am Heart Assoc. 2025;14:e042032. PMID 40970541
  16. Saito M, et al. Prognostic Implications of LV Strain Risk Score in Asymptomatic Patients With Hypertensive Heart Disease. JACC Cardiovasc Imaging. 2016;9:911-21. PMID 27344417
  17. Lertsiripatarajit P, et al. Cardiac magnetic resonance assessment of left ventricular phenotypes and prognostic implications in hypertensive heart disease. Clin Hypertens. 2026;32:e14. PMID 41953289
  18. González A, et al. Myocardial Interstitial Fibrosis in Hypertensive Heart Disease: From Mechanisms to Clinical Management. Hypertension. 2024;81:218-228. PMID 38084597
  19. Zhou D, et al. Prevalence and prognosis of left ventricular diastolic dysfunction in community hypertension patients. BMC Cardiovasc Disord. 2022;22:265. PMID 35698035
  20. Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397:1625-1636. PMID 33933205
  21. Shenasa M, et al. Hypertension, left ventricular hypertrophy, and sudden cardiac death. Int J Cardiol. 2017;237:60-63. PMID 28285801
  22. Nadarajah R, et al. Is hypertensive left ventricular hypertrophy a cause of sustained ventricular arrhythmias in humans? J Hum Hypertens. 2021;35:492-498. PMID 33674703
  23. Nwabuo CC, et al. Pathophysiology of Hypertensive Heart Disease: Beyond Left Ventricular Hypertrophy. Curr Hypertens Rep. 2020;22:11. PMID 32016791
  24. Vasan RS, et al. Prognostic Significance of Echocardiographic Measures of Cardiac Remodeling in the Community. Curr Cardiol Rep. 2021;23:86. PMID 34081212
  25. Dahlöf B, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003. PMID 11937178